Company intelligence / Profile preview
Sage Therapeutics
Cambridge, Massachusetts, United Statessagecentralsupport.com ↗
- Ownership
- Public · SAGE
- Employees
- ~512
- Development stage
- Commercial
01
Overview
Sage Therapeutics has developed the only two FDA-approved treatments indicated for postpartum depression. Its lead commercial product, ZURZUVAE® (zuranolone), was approved in August 2023 as the first oral treatment for PPD. The company also has clinical-stage programs targeting cognitive disorders such as Huntington's and Alzheimer's diseases. Some pipeline setbacks have occurred, including discontinuation of SAGE‑324 in essential tremor after negative Phase II results. As of early 2025, Sage remains independent after rejecting an unsolicited acquisition offer from Biogen and continues to explore strategic alternatives while focusing on establishing ZURZUVAE as standard of care in PPD.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →03
Partnerships
Biogen – co-development/commercialization partnership on zuranolone and other assetsShionogi – rights to develop/commercialize zuranolone in Japan/Taiwan/South Korea
04
Financials
- Market cap
- $544.9M
- Total revenue
- $31.7M
- Enterprise value
- $190.8M
Beyond the preview
Go deeper on Sage Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sage Therapeutics.